Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

"Obviously, medical conditions like diabetes and high blood pressure contribute to kidney disease, and there are other conditions that can be hereditary, so passed down through fa ...